References
- Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96:384–392
- Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol. 2003;135:219–222
- Patel DV, Horne A, House M, et al. The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology. 2013;120:773–6
- Papapetrou PD. Bisphosphonate-associated adverse events. Hormones. 2009;8:96–110
- Benderson D, Karakunnel J, Kathuria S, Badros A. Scleritis complicating zoledronic acid infusion. Clin Lymphoma Myeloma. 2006;7:145–147
- Peterson JD, Bedrossian EH Jr. Bisphosphonateassociated orbital inflammation: a case report and review. Orbit. 2012;31:119–123
- Ginat DT, Freitag SK, Kieff D, et al. Radiographic patterns of orbital involvement in IgG4-related disease. Ophthal Plast Reconstr Surg. 2013;29:261--266
- Ginat DT, Freitag SK, et al. Radiographic patterns of orbital involvement in IgG4-related disease. Ophthalmol Plast Reconstr Surg. 2013; [Epub ahead of print]
- Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol. 1999;117:837–838
- Ryan PJ, Sampath R. Idiopathic orbital inflammation following intravenous pamidronate. Rheumatology (Oxford). 2001;40:956–957
- Subramanian PS, Kerrison JB, Calvert PC, et al. Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer. Arch Ophthalmol. 2003;121:1335–1336
- Phillips PM, Newman SA. Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma. Arch Ophthalmol. 2008;126:137–139
- Sharma NS, Ooi JL, Masselos K, et al. Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med. 2008;359:1410–1411
- Procianoy F, Procianoy E. Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis. Osteoporos Int. 2010;21:1057–1058
- Seth A, Anderson DP, Albiani DA, et al. Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer. Can J Ophthalmol. 2009;44:467–468
- Yang EB, Birkholz ES, Lee AG. Another case of bisphosphonate induced orbital inflammation. J Neuroophthalmol. 2010;30:94–95
- Missotten G, Verheezen Y. Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma. Bull Soc Belge Ophthalmol. 2010;315:23–24
- Yeo J, Jafer AK. Zolendronate associated inflammatory orbital disease. N Z Med J. 2010;123:50–52
- Boni C, Kordic H, Chaloupka K. Bisphosphonate-associated orbital inflammatory disease and uveitis anterior—a case report and review. Klin Monbl Augenheilkd. 2013;230:367–369
- Reid IR, Gamble GD, et al. Characterization of and risks for the acute-phase response after zoledronic acid. J CLin Endocrinol Metab. 2010;95:4380–4387
- Dicuonzo G, Vincenzi B, Santini D, et al. Fever after zoledronic acid administration is due to increase in TNF-and IL-6. J Interferon Cytokine Res. 2003;23:649–654
- French DD, Margo CE. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina. 2008;28:889–893
- Mondelo N, Peluffo V, Parma M, et al. Toxicologia preclinical de bisfosfonatos. Medicina (B Aires). 1997;57:93–100